CDIO icon

Cardio Diagnostics

4.06 USD
+0.11
2.78%
At close Jun 13, 4:00 PM EDT
Pre-market
4.06
+0.00
0.00%
1 day
2.78%
5 days
-14.71%
1 month
-24.11%
3 months
-66.33%
6 months
-89.26%
Year to date
-84.52%
1 year
-77.13%
5 years
-98.62%
10 years
-98.62%
 

About: Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

Employees: 9

0
Funds holding %
of 7,296 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

125% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 4

0% more funds holding

Funds holding: 23 [Q4 2024] → 23 (+0) [Q1 2025]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

1.49% less ownership

Funds ownership: 6.36% [Q4 2024] → 4.86% (-1.49%) [Q1 2025]

65% less capital invested

Capital invested by funds: $2.36M [Q4 2024] → $836K (-$1.52M) [Q1 2025]

Research analyst outlook

We haven’t received any recent analyst ratings for CDIO.

Financial journalist opinion

Based on 3 articles about CDIO published over the past 30 days

Neutral
Business Wire
5 days ago
Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company's IP portfolio.
Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology
Neutral
Business Wire
2 weeks ago
Cardio Diagnostics Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced it has regained compliance with Nasdaq minimum bid price.
Cardio Diagnostics Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price
Neutral
Business Wire
3 weeks ago
Cardio Diagnostics Broadens Access to Precision Cardiovascular Care with New Practice Partnerships Across U.S. Mainland and Puerto Rico
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has the continued expansion of its reach with a new cohort of healthcare practices across the United States.
Cardio Diagnostics Broadens Access to Precision Cardiovascular Care with New Practice Partnerships Across U.S. Mainland and Puerto Rico
Neutral
Business Wire
1 month ago
Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings today announced a 1-for-30 reverse stock split of its common stock effective with the market opening on May 13, 2025.
Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split
Neutral
Business Wire
2 months ago
Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will showcase its growing portfolio of advanced cardiovascular solutions at the ACC's 74th Annual Scientific Session & Expo.
Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session
Neutral
Business Wire
4 months ago
Cardio Diagnostics Expands the Reach of its AI-Driven Precision Cardiovascular Medicine Tests by Partnering with Seven New Provider Organizations
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has announced that the Company has partnered with seven new provider organizations.
Cardio Diagnostics Expands the Reach of its AI-Driven Precision Cardiovascular Medicine Tests by Partnering with Seven New Provider Organizations
Neutral
Business Wire
5 months ago
Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced their PrecisionCHD and Epi+Gen CHD tests have received final pricing determinations from CMS.
Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests
Neutral
Business Wire
7 months ago
Cardio Diagnostics Holdings, Inc. to Sponsor and Showcase AI-Powered Solutions at the FLAACOs Annual Conference
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will sponsor and exhibit at the Florida Association of ACOs (FLAACOs) 2024 Annual Fall Conference.
Cardio Diagnostics Holdings, Inc. to Sponsor and Showcase AI-Powered Solutions at the FLAACOs Annual Conference
Neutral
Business Wire
8 months ago
Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' PrecisionCHD and Epi+Gen CHD tests have received preliminary pricing determinations from CMS.
Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests
Neutral
Business Wire
10 months ago
Cardio Diagnostics Holdings Inc. Launches CDIO.AI, A Redesigned Website Enhancing User Experience and Highlighting Our AI-Driven Cardiovascular Solutions
CHICAGO--(BUSINESS WIRE)--CDIO.AI emphasizes Cardio Diagnostics' AI-first, scalable solutions for preventing, detecting and managing cardiovascular disease.
Cardio Diagnostics Holdings Inc. Launches CDIO.AI, A Redesigned Website Enhancing User Experience and Highlighting Our AI-Driven Cardiovascular Solutions
Charts implemented using Lightweight Charts™